Join to access to all OVN content. Join for Free
The HIGH FIVE Challenge
Mel Robbins High Five Habit Tom Caravela MSL Talk Podcast High Five Challenge

The HIGH FIVE Challenge


Share This Article


Summary

In this episode, Tom Caravela delves into the transformative power of Mel Robbins' high five habit. He begins by introducing Mel Robbins and her background, then unpacks the concept and practical application of the high five habit. Tom discusses research and studies that validate its effectiveness, highlighting how it can positively impact daily intentions and mindset. The episode encourages listeners to undertake the high five challenge and invites them to share their personal experiences with this practice.

Tom Caravela, Managing Director of The Carolan Group and Host of the MSL Talk Podcast introduces the HIGH FIVE Habit and the HIGH FIVE Challenge.

Tom shares…

πŸ‘‰ Insights on the new book by @Mel Robbins, The High Five Habit

πŸ‘‰ What the High Five Habit is and how it works

πŸ‘‰ The research behind the movement and why you should consider it

πŸ‘‰ An invitation to the High Five Challenge

Click for Source
Mel Robbins, High Five Habit, Tom Caravela, MSL Talk Podcast, High Five Challenge

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Why Relationships Define Medical Affairs Leadership
OVN Avatar Kirk Shepard

Why Relationships Define Medical Affairs Leadership

Podcast
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How Medical Affairs Professionals Should Engage with Digital Opinion Leaders

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN